Summary
The inhibitory effects of several adenosine analogues, including the new A2-selective agonists 2-[p-(2-carboxyethyl)phenethylamino]-5′-N-ethylcarboxamido-adenosine (CGS 21680) and 2-hexynyl-5′-N-ethylcarbox-amidoadenosine (2-hexynyl-NECA), were investigated in vitro on human and rabbit platelet aggregation. The compounds examined inhibited ADP-induced platelet aggregation over a wide range of potency. The rank order of activity was similar between the two species thus showing that the rabbit is a useful animal model for studying the effects of adenosine derivatives on platelet aggregation. 2-Hexynyl-NECA was found to be the most potent adenosine compound of those currently available, having IC50 values of 0.10 and 0.07 μM in human and rabbit platelets, respectively. Conversely, the A1 agonists R(−)-N-6-(2-phenylisopropyl) adenosine (R-PIA), S(+)-N6-(2phenylisopropyl) adenosine (S-PIA) and 2-chloro-N6-cyclopentyl-adenosine (CCPA) were the least potent compounds with IC50 values in the micromolar range. The potency of the compounds in inhibiting platelet aggregation was found to be highly correlated with their affinity for A2 receptors as measured using 3H-CGS 21680 binding in rat brain striatum.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Born GVR, Cross MJ (1963) The aggregation of blood platelets. J Physiol 168:178–195
Bruns RF, Daly JW, Snyder SH (1980) Adenosine receptors in brain membranes: binding of N6-cyclohexyl [3H] adenosine and 1,3-diethyl-8[3H] phenylxanthine. Proc Natl Acad Sci USA 77:5547–5551
Bruns RF, Lu GH, Pugsley TA (1986) Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol Pharmacol 29:331–346
Cheng YC, Prusoff HR (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108
Cristalli G, Eleuteri A, Vittori S, Volpini R, Lohse MJ, Klotz KN (1992) 2-Alkynyl derivatives of adenosine and N-ethyladenosine-5′-uron-amide as selective agonists at A2 adenosine receptors. J Med Chem 35:2363–2368
Daly JW (1982) Adenosine receptors: target for future drugs. J Med Chem 25:197–207
Dodds WJ (1978) Platelet function in animals: species specificities. In: De Gaetano G, Garattini S (eds) Platelets: a multidisciplinary approach. Raven Press, New York, pp 45–59
Finney DJ (1978) Statistical methods in biological assay, 3rd edn. Griffin, London, pp 80–82
Haslam RJ, Cusack NJ (1981) Blood platelet receptors for ADP and for adenosine. In: Burnstock G (ed) Purinergic receptors. Chapman and Hall, London New York, pp 223–285
Haslam RJ, Rosson GM (1975) Effects of adenosine on levels of adenosine cyclic 3′,5′-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol 11:528–544
Hutchison AJ, Webb RW, Oei H, Ghai GR, Zimmerman MB, Williams M (1989) CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J Pharmacol Exp Ther 251:47–55
Hüttemann E, Ukena D, Lenschow W, Schwabe U (1984) Rα adenosine receptors in human platelet. Characterization by 5′-N-ethylcarbox-amido [3H]adenosine binding in relation to adenylate cyclase activity. Naunyn-Schmiedeberg's Arch Pharmacol 325:226–233
Jarvis MF, Schulz R, Hutchison AJ, Do UH, Sills MA, Williams M (1989) [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther 251:888–893
Lohse MJ, Elger B, Lindenborn-Fotinos J, Klotz KN, Schwabe U (1988a) Separation of solubilized A2 adenosine receptors of human platelets from non-receptor [3H]NECA binding sites by gel filtration. Naunyn-Schmiedeberg's Arch Pharmacol 337:64–68
Lohse MJ, Klotz K-N, Schwabe U, Cristalli G, Vittori S, Grifantini M (1988b) 2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 337:687–689
Londos C, Cooper DMF, Wolff J (1980) Subclasses of external adenosine receptors. Proc Natl Acad Sci USA 77:2551–2554
Maderna P, Colli S, Sirtori C, Tremoli E, Paoletti R (1985) Control of human and animal platelet aggregation by a new prostacyclin analog. Adv Prostaglandin Thromboxane Leukotriene Res 13:363–369
Paul S, Feoktistov I, Hollister AS, Robertson D, Biaggioni I (1990) Adenosine inhibits the rise in intracellular calcium and platelet aggregation produced by thrombin: evidence that both effects are coupled to adenylate cyclase. Mol Pharmacol 37:870–875
Ukena D, Böhme E, Schwabe U (1984) Effects of several 5′-carboxamide derivatives of adenosine on adenosine receptors of human platelets and rat fat cells. Naunyn-Schmiedeberg's Arch Pharmacol 327:36–42
Van Calker D, Müller M, Hamprecht B (1979) Adenosine regulates via two different types of receptors the accumulation of cyclic AMP in cultured brain cells. J Neurochem 33:999–1005
Author information
Authors and Affiliations
Additional information
Correspondence to S. Dionisotti at the above address
Rights and permissions
About this article
Cite this article
Dionisotti, S., Zocchi, C., Varani, K. et al. Effects of adenosine derivatives on human and rabbit platelet aggregation. Naunyn-Schmiedeberg's Arch Pharmacol 346, 673–676 (1992). https://doi.org/10.1007/BF00168741
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00168741